HAPPY EASTER! 50% Off Premium Subscription Claim Offer ⏰ 0d 00h 00m 00s

Codexis Earnings Calls

Q1 2025 (Upcoming)
Release date May 01, 2025
EPS estimate -$0.200
EPS actual -
Revenue estimate 10.377M
Revenue actual -
Expected change +/- 7.16%
Q4 2024 Missed
-$0.130 (-225.00%)
Release date Feb 27, 2025
EPS estimate -$0.0400
EPS actual -$0.130
EPS Surprise -225.00%
Revenue estimate 27.41M
Revenue actual 21.46M
Revenue Surprise -21.71%
Q3 2024 Missed
-$0.290 (-16.00%)
Release date Oct 31, 2024
EPS estimate -$0.250
EPS actual -$0.290
EPS Surprise -16.00%
Revenue estimate 27.41M
Revenue actual 12.833M
Revenue Surprise -53.18%
Q2 2024 Missed
-$0.320 (-23.08%)
Release date Aug 08, 2024
EPS estimate -$0.260
EPS actual -$0.320
EPS Surprise -23.08%
Revenue estimate 7.82M
Revenue actual 7.979M
Revenue Surprise 2.03%

Last 4 Quarters for Codexis

Below you can see how CDXS performed 4 days prior and 4 days after releasing the earnings report. Also, you can see the pre-estimates and the actual earnings. This information can give you a slight idea of what you might expect for the next quarter's release.

Q2 2024 Missed
Release date Aug 08, 2024
Fiscal end date Jun 30, 2024
Price on release $3.15
EPS estimate -$0.260
EPS actual -$0.320
EPS surprise -23.08%
Date Price
Aug 02, 2024 $3.30
Aug 05, 2024 $3.21
Aug 06, 2024 $3.22
Aug 07, 2024 $3.02
Aug 08, 2024 $3.15
Aug 09, 2024 $2.80
Aug 12, 2024 $2.82
Aug 13, 2024 $2.80
Aug 14, 2024 $2.82
4 days before -4.55%
4 days after -10.48%
On release day -11.11%
Change in period -14.55%
Q3 2024 Missed
Release date Oct 31, 2024
Fiscal end date Sep 30, 2024
Price on release $3.14
EPS estimate -$0.250
EPS actual -$0.290
EPS surprise -16.00%
Date Price
Oct 25, 2024 $2.91
Oct 28, 2024 $3.18
Oct 29, 2024 $3.19
Oct 30, 2024 $3.21
Oct 31, 2024 $3.14
Nov 01, 2024 $3.50
Nov 04, 2024 $3.49
Nov 05, 2024 $3.82
Nov 06, 2024 $4.01
4 days before 7.90%
4 days after 27.71%
On release day 11.46%
Change in period 37.80%
Q4 2024 Missed
Release date Feb 27, 2025
Fiscal end date Dec 31, 2024
Price on release $3.93
EPS estimate -$0.0400
EPS actual -$0.130
EPS surprise -225.00%
Date Price
Feb 21, 2025 $4.18
Feb 24, 2025 $4.11
Feb 25, 2025 $4.01
Feb 26, 2025 $4.16
Feb 27, 2025 $3.93
Feb 28, 2025 $3.04
Mar 03, 2025 $2.74
Mar 04, 2025 $2.68
Mar 05, 2025 $2.73
4 days before -5.98%
4 days after -30.53%
On release day -22.65%
Change in period -34.69%
Q1 2025 (Upcoming)
Release date May 01, 2025
Fiscal end date Mar 30, 2025
Price on release -
EPS estimate -$0.200
EPS actual -
Date Price
Apr 11, 2025 $2.35
Apr 14, 2025 $2.30
Apr 15, 2025 $2.25
Apr 16, 2025 $2.12
Apr 17, 2025 $2.11

Codexis Earnings Call Transcript Summary of Q4 2024

Forward-Looking Statements

Codexis emphasized that investors should be cautious about relying on forward-looking statements given the associated risks and uncertainties.

Business Progress

  • Pharma Manufacturing Recovery: Codexis has revitalized its core pharmaceutical manufacturing business and is now on a growth trajectory.
  • Cost Reduction & Profitability Path: Significant cost reduction measures have strengthened the balance sheet, creating a clearer path to profitability.
  • ECO Synthesis Platform: Introduction of the ECO Synthesis platform for enzymatic oligonucleotide synthesis is a focal point, with potential for revenue growth especially in 2025.

Product Development and Market Engagement

  • Engagement with Drug Innovators: Codexis has seen increased engagement with siRNA innovators, completing feasibility studies with multiple leading companies.

Codexis Earnings History

Earnings Calendar

FAQ

When is the earnings report for CDXS?
Codexis (CDXS) has scheduled its earnings report for May 01, 2025 before the markets open.

What is the CDXS price-to-earnings (P/E) ratio?
CDXS P/E ratio as of Apr 17, 2025 (TTM) is -2.64.

What is the CDXS EPS forecast?
The forecasted EPS (Earnings Per Share) for Codexis (CDXS) for the first fiscal quarter 2025 is -$0.200.

What are Codexis's retained earnings?
On its balance sheet, Codexis reported retained earnings of $21.46 million for the latest quarter ending Dec 31, 2024.

What Is an Earnings Report?
An earnings report is usually issued quarterly (Q1, Q2, Q3 & Q4) by public companies to report their performance. Earnings reports typically include net income, earnings per share, earnings from continuing operations, and net sales. Looking at the earnings report investors can start gauge the financial health of the company and make even better decisions whether to buy, sell, or stay in the company. Fundamental analysts and value investors will typically hunt for stocks that continue to show good financial ratios and use a decline as an exit point. One of the most anticipated numbers for analysis is earnings per share because it indicates how much the company earned for its shareholders. The report will also indicate a possible dividend.

Earnings Report Content
Earnings reports generally provide an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. These figures are typically measured against previous quarters/years. Furthermore, the earnings report usually includes a summary and analysis from the CEO or company spokesman, alongside a more general view of the financials and future forecast.

What To Know About Earnings Reports?
Announcement of earnings for a stock, particularly for well followed large-capitalization stocks, can move the market. Stock prices can fluctuate wildly on days when the quarterly earnings report is released. Despite good reports, stocks may very well fall if the investors were expecting more or they believe the next quarter will not be as good. Investors always try to be ahead of the market and future earnings/losses are often discounted into the current price of the stock. It is natural for stocks to start to move in either direction a few days before the release of an earnings report.
Click to get the best stock tips daily for free!
ABOUT CODEXIS
Codexis
Codexis, Inc. discovers, develops, and sells enzymes and other proteins. It offers biocatalyst products and services; intermediate chemicals products that are used for further chemical processing; and Codex biocatalyst panels and kits that enable customers to perform chemistry screening. The company also provides biocatalyst screening and protein engineering services. In addition, it offers CodeEvolver protein engineering technology platform, whi...
GOLDEN STAR
Ticker Change Signal Date
F
FNA
$12.99
0.85% Apr 15
V
VCSH
$78.34
0.370% Apr 15
F
FTSM
$59.85
0.117% Apr 15
S
SLQD
$49.97
0.260% Apr 15
I
ISTB
$48.11
0.239% Apr 15

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE